O. Manzke

发表

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.

V. Diehl, C. Wickenhauser, Thomas P. Davis, 2002, Blood.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

V. Diehl, A. Engert, M. Jensen, 2016 .

Vaccination of multiple myeloma patients with idiotype‐pulsed dendritic cells: immunological and clinical aspects

V. Diehl, H. Tesch, H. Bohlen, 2000, British journal of haematology.

Identification and characterization of embryonic stem cell‐derived pacemaker and atrial cardiomyocytes

B. Fleischmann, W. Bloch, J. Hescheler, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.

V. Diehl, H. Tesch, D. Kube, 1993, Blood.

antibodies in combination with bivalent CD28 antibodies leukemia by autologous T cells activated with CD3 x CD19 bispecific Lysis of malignant B cells from patients with B-chronic lymphocytic

V. Diehl, H. Tesch, D. Kube, 2011 .

CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T‐cell reactivity against autologous leukemic cells in pediatric B‐ALL bone marrow

V. Diehl, F. Berthold, H. Tesch, 1999, International journal of cancer.

Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.

V. Diehl, H. Tesch, H. Bohlen, 1997, Journal of immunological methods.

Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.

V. Diehl, B. Dörken, H. Tesch, 1993, Cancer Research.

Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.

V. Diehl, H. Tesch, H. Abken, 1997, Cancer research.

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

V. Diehl, A. Engert, M. Jensen, 1998, Annals of Hematology.

Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab

A. Thall, A. Engert, H. Schulz, 2002, Journal of Neuro-Oncology.

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

L. Staudt, R. Gascoyne, G. Salles, 2014 .

Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses

V. Diehl, H. Tesch, H. Bohlen, 2001, International journal of cancer.

Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

V. Diehl, H. Tesch, A. Gossmann, 2001, International journal of cancer.

CD3× anti‐nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors

V. Diehl, B. Fleischmann, H. Hoogenboom, 1999, International journal of cancer.

Effects of methotrexate on normal articular cartilage in vitro and in vivo

H. Bohlen, O. Manzke, J. Neidel, 1998, Annals of the rheumatic diseases.

Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.

V. Diehl, O. Cochet, B. Fleischmann, 1999, Cancer research.

Carcinoembryonic Antigen ( CEA )-specific T-Cell Activation in Colon Carcinoma Induced by Anti-CD 3 3 Anti-CEA Bispecific Diabodies and B 7 3 Anti-CEA Bispecific Fusion Proteins 1

V. Diehl, O. Cochet, B. Fleischmann, 1999 .

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.

V. Diehl, B. Lathan, H. Tesch, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation.

V. Diehl, H. Tesch, H. Bohlen, 1994, Journal of immunological methods.

Functional Characteristics of ES Cell–derived Cardiac Precursor Cells Identified by Tissue-specific Expression of the Green Fluorescent Protein

B. Fleischmann, S. Viatchenko‐Karpinski, W. Bloch, 1998, The Journal of cell biology.

Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.

V. Diehl, H. Stein, H. Herbst, 2002, Blood.

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

R. Greil, U. Jäger, L. Trümper, 2021, International Journal of Hematology.

Monoclonal Antibody Therapy of Patients with Non-Hodgkin´s Lymphomas

V. Diehl, H. Tesch, H. Bohlen, 1999, Oncology Research and Treatment.

Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L

M. Beyer, J. Schultze, M. von Bergwelt-Baildon, 2006, Leukemia & lymphoma.

Treatment of patients with malignant lymphomas with monoclonal antibodies

V. Diehl, H. Tesch, H. Bohlen, 2000, Bone Marrow Transplantation.

Modulation of MUC1 and blood group antigen expression in gastric adenocarcinoma cells by cytokines.

P. Schirmacher, S. Baldus, H. Dienes, 2003, Cytokine.

Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.

V. Diehl, J. Wolf, M. Beyer, 2005, Cancer research.

E V ects of methotrexate on normal articular cartilage in vitro and in vivo

H. Bohlen, O. Manzke, J. Neidel, 1998 .

ects of methotrexate on normal articular cartilage in vitro and in vivo

H. Bohlen, O. Manzke, J. Neidel, 1998 .

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

R. Greil, U. Jäger, L. Trümper, 2019, Journal of Clinical Oncology.

Role and Extent of Surgery in Multimodality Treatment

V. Diehl, W. Scheithauer, V. Budach, 1999, Oncology Research and Treatment.

Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.

H. Bohlen, G. Moldenhauer, O. Manzke, 1993, Cancer research.

M. Jensen, A. Engert, O. Manzke, 2016 .

Functional Characteristics of ES Cell–derived Cardiac Precursor Cells Identified by Tissue-specific Expression of the Green Fluorescent Protein

B. Fleischmann, S. Viatchenko‐Karpinski, K. Addicks, 1998, The Journal of cell biology.